Sirius licenses sepsis markers to Tm Bioscience
This article was originally published in Clinica
Molecular test developer Tm Bioscience has excusively licensed from fellow Canadian company Sirius Genomics specific biomarkers associated with drugs used for treating severe sepsis. Toronto-based Tm Bioscience will incorporate these markers into a test that identifies patients who would respond well to vasopressin and Xigris, the two drugs commonly used to treat the condition. The product, scheduled for launch in the second half of 2007, is expected to generate sales of over US$100m in the first three years of commercialisation.